3Scott JC, Hochberg MC. Osteoarthritis I: epidemiology. Md State Med J, 1984, 33 (9): 712
4Amett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum, 1988, 31 (3): 315
5LequesneMG, MeryC, SamsonM, etal. Indexes of severity for osteoarthritis of the hip and knee. J Rheumatol Suppl, 1988, 73 (13):1
6VennG, NietfeldJJ, Duits AJ, etal. Elevated synovial fluid levels of interleukin 6 and tumor necrosis factor associated with early experimentalcanineosteoarthritis. Arthritis Rheum, 1993, 36 (6): 819
7Pelletier JP, Roughley PJ, DiBattista JA, et al. Are cytokines involved in osteoarthritic pathophysiology? Semin Arthritis Rheum,1991, 20 (6Suppl2): 12
8Romas E, Martin TJ. Cytokines in the pathogenesis of osteoporosis.Osteoporos Int, 1997, 7 (Suppl 3): 47
9Dean DD, Martel- Pelletier J, Pelletier JP, et al. Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. J Clin Invest, 1989, 84 (2): 678
10Hordon LD, Bird HA, Cooper EH. Renal tubular dysfunction in rheumatic diseases. BrJRheumatol, 1991, 30 (2): 115
1Wind W, Smolinski RJ. Reliability of common knee injection sites with low-volume injections. J Arthoplasty, 2004,19:858-861.
2Espallargues M, Pons JM. Efficacy and safety of viscosupplementation with HylanG-F 20 for the treatment of knee osteoarthritis: a systematic review. Int J Technol Assess Health Care, 2003,19:41-56.
